Industry | 3 September, 2025 at 10:33 AM
Morphosis Capital closes €130 million fund
Morphosis Capital Partners, a growth capital fund, has successfully closed its second fund, Morphosis Capital Fund II, at €130 million.
Morphosis Capital Partners, a growth capital fund, has successfully closed its second fund, Morphosis Capital Fund II, at €130 million.
The European Bank for Reconstruction and Development (EBRD) has allocated €15 million to Morphosis Capital Fund II, a private equity fund managed by Morphosis Capital Partners.
Morphosis Capital Fund II, a growth capital fund focused on developing high-growth SMEs, announces its first investment outside Romania.
This acquisition marks the third transaction for Morphosis, having committed to deploy over 30% of the Fund's investable capital within the first 7 months of its first closing.
Electro-Alfa International, a Romanian electrical equipment manufacturer, has announced plans for an Initial Public Offering (IPO) on the Bucharest Stock Exchange (BVB).
Global life sciences M&A activity increased by 81% in 2025 to $240 billion, driven by Big Pharma's large-scale deals, despite fewer overall transactions. The surge reflects companies prioritising innovations ready for launch as they face widening growth gaps.
Romania's Ministry of Finance will conduct its first public offering of Fidelis government bonds for 2026 between January 16 and 23 on the Bucharest Stock Exchange. This marks the 32nd offering since the Fidelis program resumed in July 2020.
Romania's final electricity consumption fell by 0.7% in the first 11 months of 2025 compared to the same period in 2024, according to data published by the National Institute of Statistics (INS).
Romania has the second-lowest consumer prices in the European Union, with costs 36% below the EU average in 2024, according to new Eurostat data released in December 2025.